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swelling and rupture of mitochondria and a
reduction in ATP/ADP ratio compared with
untreated cells. These effects ofconcanavalin
A were markedly reduced by oc-methyl-D-
mannopyranoside, indicating that the conca-
navalin A binding sites on the LAT cells are
sterically related to this sugar. The observed
effects on the mitochondria may provide an
explanation for the known cytotoxic effect of
concanavalin A on ascites tumour cells.
ACCENTUATION OF CHLORAM-
BUCIL EFFECT BY VARIOUS ADDI-
TIVES ON RAT TUMOUR CELLS IN
CULTURE, T. K. Basu, N. P. Bishun,
R. W. Raven and D. C. Williams, The Marie
Curie Memorial Foundation, Oxted.
Chlorambucil has been used extensively
for the treatment of chronic lymphoblastic
leukaemia but the development of resistance
to the drug has restricted its usefulness. An
understanding of its mode of action when
used in combination with other substances
may lead to a wider application of the drug
in cancer therapy. In recent years vitamin
A and caffeine have been reported to enhance
the anti-tumour effect of certain alkylating
agents (Cohen and Carbone, J. natn. Cancer
Inst., 1972, 48, 921; Cohen, J. natn. Cancer
Inst., 1972, 48, 927).
In view of these observations, we have
investigated the combined effect of chloram-
bucil, vitamin A, caffeine and phenobarbitone
on an established tumour cell line derived
from a male rat breast. The viable cell
counts in chlorambucil (Chl), Chl + pheno-
barbitone (Pb), Chl + Pb + caffeine (Caf)
and Chl + Pb + Caf + vitamin A were610%,
4400, 40% and 25% of the control counts
respectively after 3 days, at which time these
combinations had their greatest efficacy.
FACTORS INFLUENCING THE ES-
TABLISHMENT OF HUMAN TU-
MOUR CELLS AS A XENOGRAFT,
L. M. Cobb, B. C. V. Mitchley and J. M. F.
Wood, Huntingdon Research Centre and
Chester Beatty Research Institute, London.
In recent years it has been possible to
obtain growth of human tumours in
" immune deprived " rodents. We have
observed that certain types of tumour, for
example, carcinoma ofthe colon and rectum,
almost invariably become established and
others have proved difficult to grow. During
this work a number of factors have emerged
that seem likely to influence the establish-
ment ofhuman tumour grafts. These factors
include species of recipient, method of
immune deprivation, blood levels of sex
hormones in the recipient and size and site of
implant.
CHLORPROMAZINE STIMULATION
OF PROLACTIN SECRETION: A
TEST OF PITUITARY FUNCTION,
R. G. Wilson, B. N. Cole, A. R. Boyns and
A. P. M. Forrest, Department of Clinical
Surgery, University of Edinburgh and Teno-
vus Institute of Cancer Research, Cardiff.
Phenothiazines cause a rise in plasma
prolactin in normal subjects when given
orally or by injection (Frantz et al. and
Bryant and Greenwood, 1972. Ciba Sym-
posium Lactogenic Hormones. Ed. G. B. W.
Wolstenholme and J. Knight. London and
Edinburgh: Churchill Livingstone). Turking-
ton (J. clin. Endocr. 1972, 34, 247) described
the acute stimulation of prolactin secretion
using 50 mg of chlorpromazine i.m. The
prolactin response was diminished in hypo-
pituitarism.
Six patients with breast cancer were
similarly tested. The plasma prolactin
response was measured by homologous radio-
immunoassay. The mean basal plasma
prolactin was 13-7 + (s.e.) 7-5 mAmp/ml.
This rose to a peak of 77-3 ± 11-4 mAmp/ml
within 2 hours of the injection.
One to three months after yttrium
implant pituitary ablation for advanced
breast cancer, patients received a similar
stimulation ofresidual prolactin cell function.
This was in addition to the standard test of
growth hormone response to insulin reduced
hypoglycaemia (Stewart et al., J. Endocr.,
1971, 50, 41). The two tests have been
compared and both have demonstrated
positive responses in the case of incomplete
pituitary ablation, as proven by post-mortem
histology of the gland.
The chlorpromazine test is simple and
possibly safer than the standard test in
hypophysectomized patients.
THE EFFECTS OF FENTAZIN ON
ANDROGEN METABOLISM IN DMBA
INDUCED RAT ADENOCARCINO-
MATA, W. R. Miller, R. Buchan and
A. P. M. Forrest, Department of Clinical
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Fentazin (perphenazine), a phenothi-
azine, increases circulating prolactin levels
by inhibiting prolactin inhibiting factor.
(Pearson et al., Trans. Am. Physicns, 1969,
32, 225). Female Sprague-Dawley rats aged
30 days were started on daily subcutaneous
injections either of Fentazin (5 mg/kg body
weight) or vehicle (02% citric acid). Both
groups of animals received DMBA (5 mg
i.v.) when aged 50 days. The in vitro meta-
bolism of [3H]dehydroepiandrosterone and
[3H]testosterone was determined in adeno-
carcinomata subsequently appearing in the
rats.
Adenocarcinomata from the Fentazin
treated animals displayed greater meta-
bolism of testosterone than those from
control animals whereas the transformation
of dehydroepiandrosterone was similar in
both groups. The increase in testosterone
metabolism was largely accounted for by a
significant increase in 5-co-reductase activity.
These results suggest that prolactin may
modify the intracellular environment of
steroid hormones in rat adenocarcinomata.
TRIPLE CHEMOTHERAPY IN ACUTE
NON-LYMPHOCYTIC LEUKAEMIA,
J. J. Fennelly and L. O'Connell, Our Lady's
Hospice, Dublin.
Thirty-two patients with acute non-
lymphocytic leukaemia (22 myeloid, 2 mono-
blastic, 3 myelomonoblastic, 2 promyelocytic,
3 blast crisis) have been treated with com-
bined daunorubincin 1 mg/kg i.v. x 1 cyto-
sine arabinoside 2 mg/kg x 5 and vincristine
1 mg i.v. x 1 in 5-day cycles and followed by
6-mercaptopurine and cyclophosphamide
when remission was induced, with reinduction
at 3-monthly intervals. Sixty per cent of
patients went into full remission, which has
lasted from 6 months to 2 years. Two
patients with acute promyelocytic leukaemia
developed coagulation problems which were
controlled by EACA and then went into full
remission. Two patients with acute mono-
blastic and myelomonoblastic leukaemia
went into full remission on this programme.
One patient who was extremely ill during
induction of remission developed a severe
neuropathy. Alopecia was a problem with
higher dosage of daunorubicin and cardio-
toxicity occurred in 2 patients. Reinduction
at 3-monthly intervals with triple chemo-
therapy was smooth and in our opinion
contributes tothe prolongedremissioninthese
cases. Age group did not significantly affect
remission rate.
FAMILIAL HODGKIN'S DISEASE, J. J.
Fennelly and A. McBride, Our Lady's
Hospice, Dublin.
Three girls in one family developed
nodular sclerosing Hodgkin's disease in 1967,
1970 and 1973 respectively. In addition,
other members have had multiple viral
infections, including infectious mononucleosis
and herpetic infections. An intensive study
of chromosomes HL-A typing, blood groups,
immunoglobulins immunity (DNCB Mantoux
test, lymphoblast transformation) has been
carried out on all siblings (5) and parents and
is presented, in addition to complete studies
of viral antibodies, with emphasis on EB
virus. The triple occurrence in this family
at such time intervals suggests that some
genetic factor, i.e. depressed immunity must
in these cases provide an underlying milieu
in which a viral infection may manifest itself
as Hodgkin's disease.
USE OF THE CARCINOEMBRYONIC
ANTIGEN AND SERUM ENZYME
CHANGES IN THE DETECTION OF
METASTATIC INVOLVEMENT OF
THE LIVER, L. Steele, E. H. Cooper,
A. Munro Neville and M. S. Losowsky,
Department of Cancer Research, University
of Leeds, and Chester Beatty Research
Institute, London, and Department of Medi-
cine, St James's University Hospital, Leeds.
The combination ofestimations ofcarcino-
embryonic antigen (CEA) with certain serum
enzymes (y glutamyl transpeptidase (yGT)
and leucine aminopeptidase (LAP) can
enhance the separation of controls from
patients with primary colorectal cancer and
those with metastatic involvement of the
liver.
yGT contributes to this discrimination in
both the primary and secondary case. The
mean values were: (i) control 13-94 ± 7-65;
(ii) primary 21'65 i 12-20 and (iii) metastatic
139-34 ± 96-22.
On the other hand, the LAP was elevated
only in metastatic involvement of the liver
and did not rise before the yGT exceeded
100 units: (i) control 41-55 ± 9-20; (ii)
primary 40-27 + 14-38 and (iii) metastatic
96-81 + 50-39.